Choose Ketamine was founded in 2021 with the intention of providing affordable and accessible treatments to those suffering from depression, anxiety and PTSD that have not found relief in traditional approaches. Already present in 12 states, this funding will support continued expansion into 50 states and additional hiring in order to provide expert clinical providers and psychedelic guides.

Mark Holland, co-founder and CEO of Choose Ketamine noted: “Our team is incredibly passionate about delivering positive outcomes to patients who can benefit from our services – it’s truly fulfilling work.”

Charbel Zreik, Founder and Managing Principal of Manifestations Capital commented: “We’re delighted to partner up with these talented entrepreneurs and be part of their mission to revolutionize mental health care.”

The team at Choose Ketamine is dedicated to optimizing patient outcomes through effective ketamine protocols. In addition to oral ketamine assisted therapy experiences, they are exploring additional therapeutic modalities such as sound and light therapies that may contribute toward reinforcing patient wellbeing. With this financing round complete, they are now able to take steps towards making these treatments available across the country on their technology platform.

The post Choose Ketamine Complete Capital Raise to Expand Technology Platform appeared first on Psychedelic Chronicle.

Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using cutting-edge science to harness the powerful medicinal qualities of psychedelics. The company specializes in research and development transformation of biomedical sciences knowledge into pharmaceutical drugs and nanotech delivery systems for treating psychiatric and neurological conditions.

What is a New Chemical Entity?

A new chemical entity, as defined by the U.S. Food and Drug Administration, is a drug that contains no active moiety that has been previously approved for use in any other capacity by the FDA in any other application submitted under section 505 of the Federal Food, Drug, and Cosmetic Act.

The active moiety is the molecule or ion that causes the drug substance to have a physiological or pharmacological effect. It does not include any appended molecules that make it an ester, salt, or another noncovalent derivative (such as being complex, chelate, or clathrate).

An NCE is a molecule created by the innovator company earlier on in the drug development process. After it goes through clinical trials, it has the potential to turn into a treatment for some diseases.

According to the Food and Drug Administration Amendments Act of 2007, any new chemical entities must be reviewed by an advisory committee before being approved by the FDA.

Opportunities for Biomind Labs NCE Triptax

Alejandro Antalich, CEO of Biomind Labs outlined the opportunity with the NCE stating that the move was a new major step in Biomind Lab’s expansion in the United States market and the focus to upgrade the company’s clinical pipeline.

Mr. Antalich believes that the NCE Triptax could potentially be used as an active ingredient in Biomind’s novel formulations to treat depression, more specifically Treatment-Resistant Depression (TRD). TRD is a Major Depressive Disorder diagnosis given to adults who have not responded adequately to at least two different antidepressants after taking them for an adequate amount of time.

The Company submitted a briefing package on the NCE Triptax to the Division of Psychiatry, Center for Drug Evaluation and Research at the FDA and is waiting for further feedback.

The Pre-IND meeting is an integral part of the U.S. regulatory approval process that gives both the Company and FDA a chance to talk about the NCE development plan as well as receive guidance from the FDA on any new clinical trials regarding Triptax that may be conducted by the Company in the future.

Biomind Labs Current Updates

Biomind Labs is focused on providing patients with access to affordable and modern-day treatments by developing novel pharmaceutical formulations of the main psychedelic molecules: N, N-dimethyltryptamine (“DMT”), 5-MeO-DMT meclazine.

The announcement of the Pre-IND meeting with the FDA comes as Biomind Labs is completing the processing of clinical data from the first phase of a II trial for BMND01, a novel candidate drug for Treatment-Resistant Depression.

The CEO said that the company’s primary objective is to quickly move the clinical pipeline forward so that the first registered pharmaceutical drug can be made available to millions of patients worldwide. They are also taking into account what is needed to secure funding for large-scale clinical trials, such as demonstrating efficacy and safety, complying with regulatory authorities, and ensuring democratic access.

The post Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax appeared first on Psychedelic Chronicle.

About Silo Pharma

Silo Pharma is a biotechnology startup that wants to combine conventional medications with psychedelic research for people suffering from conditions like post-traumatic stress disorder (PTSD), Alzheimer’s disease, and other rare neurological diseases. Silo aims to discover assets that can be licensed and financed so that important research may be done, which the company believes will benefit patients and the healthcare sector.

Silo Pharma Z-Pod Ketamine Development Partnership with Zylö Therapeutics

Silo Pharma is developing the clinical development of ketamine using ZTI’s Z-pod technology in collaboration with joint venture partner Zylö Therapeutics, Inc. (ZTI). The Company has chosen to pursue fibromyalgia as a first indication based on preclinical research showing that the Z-pod can retain and deliver ketamine in a time-released manner.

SP-26 has yielded previous positive results in lessening neuropathic nerve pain. This safety evaluation study will provide the data needed to understand what the maximum tolerated dosage is, which will be useful for our future trials.

The SP-26 compound will now be put through a series of Safety Evaluation Studies using mini pigs in an ascending (descending) dosing regimen to test its tolerability. The study’s data is estimated to become available at the beginning of 2023.

Silo Pharma is diligently working with a regulatory partner to assemble an FDA Pre-Investigational New Drug (IND) package for SP-26, a never-before-seen topical formulation of ketamine that has been officially named SPC-26. This new drug candidate is being considered as a treatment for fibromyalgia and the Company intends to gain approval through a 505(b)(2)regulatory pathway.

Ketamine Treatment for Fibromyalgia

The Winter 2021 edition of The Ochsner Journal, a peer-reviewed quarterly medical journal, published an abstract titled Systematic Review of the Use of Intravenous Ketamine for Fibromyalgia.

The Ochsner Journal is a pioneering nonpredatory, open-access publishing initiative: the Journal does not charge authors any publication fees, and the complete text of every piece is freely available online and in print. The “platinum model” of open-access publishing is well-recognized in academic publishing.

Fibromyalgia is a complex disorder that affects 1% to 5% of the population and manifests as widespread chronic musculoskeletal pain without any physical or laboratory signs of a specific pathologic process.

Background

The mechanism is still being explored, but it suggests that central sensitization and disordered pain regulation at the spinal cord and supraspinal levels result in an imbalance between excitation and inhibition. This may then alter the central nervous system’s nociceptive processing.

Nociceptive hypersensitivity is a condition in which the brain and spinal cord are excessively sensitive to pain. The activity of the N-methyl-D-aspartate receptor (NMDAR)–mediated glutamatergic synaptic transmission in the spinal cord and brain causes it. The study of ketamine’s use as an intravenous medication to treat fibromyalgia has grown because it may reduce the induction of synaptic plasticity and maintenance of chronic pain states, making it an NMDAR antagonist.

Methods

The researchers conducted a literature search with the goals of investigating the impact of intravenous ketamine administration on pain relief, detecting unwanted effects, and emphasizing the necessity for clinical trials to evaluate ketamine infusion therapy protocols in patients with fibromyalgia.

The team used the keywords “fibromyalgia,” “chronic pain,” “ketamine,” “intravenous,” and “infusion” to find 7 articles including 118 people who satisfied the inclusion criteria.

Results

Clinical studies relatively recently discovered that there is a slight decrease in pain (for only a few hours after the ketamine infusion) when intravenous, low-dose ketamine infusions are administered. It’s most likely because of fibromyalgia patients’ central sensitization to nociception via NMDAR blockade.

According to case studies, administering a greater total amount of ketamine and continuing to administer it more frequently may be linked to better pain alleviation and longer-lasting analgesia. A second neurotransmitter release may be behind this result.

Conclusion

This systematic review found a dose-response relationship, suggesting that intravenous ketamine may help with fibromyalgia.

The post Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment appeared first on Psychedelic Chronicle.

Numinus strives to be at the cutting edge of psychedelic-assisted therapies that are both innovative and safe. Numinus VP, Scientific Research, Innovation & Laboratory Operations Sharan Sidhu said the Numinus team developed the Psilocybe tea bag with scientific precision in mind.

The VP stated that the company’s best-in-class team and resources allow Numinus to control the full production process, from growth to finished product manufacturing, to deliver a fully standardized product.

History of Psilocybe Psiloycybin Tea Bags

The study of the tea bag focused on developing processing and procedure to deliver 25mg per dose using Numinus’ verified Psilocybe cubensis strains.

Psilocybe cubensis is a species of psychedelic mushroom with primary active compounds psilocybin and psilocin. The most popular strain of psilocybin is known as Stropharia cubensis. It belongs to the fungus family Hymenogastraceae and is the most well-known psilocybin mushroom due to its wide presence and simple cultivation.

Numinus’ Psilocybe tea bag will be studied in a phase 1 trial of people receiving experiential training for psilocybin-assisted therapy, to use it in Numinus’ research, including trials at Cedar Clinical Research, which is Numinus’ clinical trial management division.

About Numinus Wellness

Numinus Wellness is s mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies. The company helps people recover from mental health difficulties and live a healthy life by developing and delivering innovative mental health care as well as providing safe, evidence-based psychedelic-assisted therapies.

The Numinus model, which includes psychedelic production, research, and treatment at clinics, is leading the charge for a shift in emphasis from treating symptoms of depression, anxiety, trauma, pain, and substance addiction to healing rather than managing them.

Psilocybe Psiloycybin Tea Bag Health Canada Approval

Health Canada has also received an application to include the product on the psilocybin supplier list for the federal Special Access Program. If approved, healthcare providers would be able to offer psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with a demonstrable need.

Chief Scientific Officer Dr. Paul Thielking pointed out the benefits of the standardized dose mushroom tea bags.

“Numinus recognizes that solid therapeutic products, such as whole mushrooms or pills, might be unappealing or difficult to use by certain populations, such as some people receiving palliative care for serious illnesses. This new product is part of our commitment to increasing accessibility to psychedelic-assisted therapies for those in need while contributing to the growing research that suggests psilocybin use in combination with therapy may be highly effective for treating mental health disorders.”

The post Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use appeared first on Psychedelic Chronicle.

atai Life Sciences N.V. (Nasdaq: ATAI) recently announced the dosing of the first subject in their Phase 1 SAD trial of VLS-01, a form of N, N-dimethyltryptamine (DMT) for the treatment of treatment-resistant depression (TRD).

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company that aims to transform the treatment of mental health disorders. atai is a new, rapidly growing company that was formed in 2018 to address the significant unmet need and lack of innovation in the mental health treatment market. atai’s mission is to identify, acquire, and incubate innovative therapies for depression, anxiety, addiction, and other mental health issues.

atai aims to responsibly advance the development of new medicines across its enterprises by pooling resources and best practices to create clinically meaningful and long-term behavioral change in persons with mental illness. The company’s goal is to treat mental health disorders so that people all over the world can live happier lives.

atai Life Sciences Phase 1 Trial of Synthetic DMT VLS-01

The trial is designed to compare the bioavailability of buccal (inside the cheek) versus IV (intravenous) formulations of VLS-01, as well as assess its safety and tolerability administered by both routes. In addition, the pharmacodynamics study will use qEEG (quantitative electroencephalography) measures and other tools to evaluate DMT’s effects.

Buccal VLS-01 has the potential to provide a psychedelic experience that lasts only 30 to 45 minutes, as opposed to other compounds which may require the patient to be monitored for four hours or more. As a result, clinic visits may be shorter than with other drugs.

The trial not only encompasses the use of atai’s IDEA-1 digital therapeutic app, but also behavioral activation therapy, group therapy, and patient monitoring post-dosing. These behavioral assessments from the trial aim to provide data that can be used to design future Phase 2 clinical trials of VLS-01. The pharmacokinetic and safety readouts from these trials will also inform the trial design.

The Need for Psychedelics in Treatment-Resistant Depression

Approximately 100 million people live with treatment-resistant depression worldwide – or a third of all persons suffering from depression – who are undertreated or unresponsive to existing therapy options. In addition to its impact on patients, families, and caregivers, TRD has a major economic cost for healthcare systems and health insurance companies.

On average, TRD patients have medical expenses that are twice as high as non-TRD major depressive disorder (MDD) patients. This is due to more inpatient visits and hospital stays that are over one-third longer.

Srinivas Rao, Chief Scientific Officer of atai Life Sciences recently expanded on the need stating, “Exploring novel approaches to drug delivery can potentially simplify in-clinic administration and allow greater pharmacokinetic control of the psychedelic experience and its overall duration of hallucinogenic effects.”

atai said the company is pleased to see the trial move forward as they establish the safety and tolerability of the compound with topline results anticipated in H1 2023.

“Given the scale of the depression crisis, the impact on patients and families could be enormous,” said Senior Vice President of Early Development of atai Life Sciences, Glenn Short.

The post atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial appeared first on Psychedelic Chronicle.

The first #63/405,786 is a patent application for the use of psilocybin to treat patients with fibromyalgia while the other patent, #63/375,305 expands the intellectual property related to the company’s development of TRP-8803.

About Tryp Therapeutics

Tryp Therapeutics is a cutting-edge biotechnology company that is focused on developing molecules related to psilocybin to treat diseases without effective medical treatments presently available with a goal to provide these treatments through accelerated regulatory pathways.

Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program is dedicated to the creation of synthetic psilocybin-related compounds as a new class of drugs for treating chronic pain, binge eating, and other indications.

Tryp Therapeutics Fibromyalgia Focused Treatment

The firm is readying for a Phase 2a clinical trial at the University of Michigan to determine the safety and preliminary efficacy of psilocybin-assisted therapy in people with fibromyalgia.

The clinical trials are expected to back up the promising preclinical findings discovered by Tryp in an animal model of nociplastic pain. Once granted, the new patent will give Tryp with Intellectual Property Protection for fibromyalgia by utilizing its psilocybin-based candidates.

Fibromyalgia is a condition that causes widespread pain and fatigue, as well as problems with sleep, memory, and mood. Existing treatments for fibromyalgia are not very effective and often have unpleasant side effects.

After one year, less than 10% of fibromyalgia patients stick to approved treatments, and around 30% of patients take opioids even though there is no evidence that they work and the known risk of addiction or overdose.

TRP-8802 & TRP-8803 Overview

Tryp is currently enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida. The company also announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia.

TRP-8803 is a psilocybin-based product that uses a different formulation and method of administration to improve efficacy, safety, and patient experience.

TRP-8802 is being used by Tryp to test the feasibility of utilizing psilocybin-related compounds for certain neuropsychiatric disorders. TRP-8803, which is being developed at the same time, will be studied in future trials where it indicates efficacy.

TRP-8803 is an improved version of psilocybin that overcomes the limitations of other administration routes, including oral, nasal, and sublingual.

The second provisional patent will continue to protect TRP-8803’s unique psilocybin-based drug. The primary goal of the provisional patent application is to improve the chemical properties of TRP-8803, allowing it to be more stable and suitable for use in TRP-8803’s original formulation and route of administration.

The post Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio appeared first on Psychedelic Chronicle.

Biomind Labs are focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules. The goal of Biomind Labs is to use medical breakthroughs to create new nanotech delivery systems that can adequately address a range of psychiatric and neurological issues.

Biomind Laboratories is using its acceleration platform to develop novel pharmaceutical formulations of the key psychedelic compounds N, N-dimethyltryptamine (“DMT“), 5-MeO-DMT, and mescaline for a variety of therapeutic applications. Biomind Labs’ mission is to provide patients with access to cost-effective and contemporary therapies.

According to Biomind Labs, 10-30% of persons with depression have treatment-resistant symptoms, as well as difficulties in social and occupational functioning, a deterioration of physical health, poor quality of life, suicide ideation and attempts, self-injurious behavior, high relapse rate, and increased health care utilization.

The objectives of the trial are to establish the safety and tolerability of DMT. In addition to evaluating side effects, this trial will also allow Biomind to explore the origin of the observed side effects, given that different associated physiological, behavioral, and cognitive markers will be collected before, during, and after the trial.

Read More: August 2022 – Biomind Labs Inc. Add Former FDA Director Dr. Thomas Laughren as Medical Advisor for Clinical Trials.

Biomind Labs CEO Alejandro Antalich Feedback on Clinical Trial Milestone

“The results of this first part of the world’s first clinical trial to test an inhaled formulation of DMT are expected to be ready in October 2022. The trial is designed with a fixed ascending two dose, concentration-response study, allowing DMT to be rapidly delivered directly into the systemic circulation in approximately 10 minutes, bypassing the first-pass metabolism, which is recognized as a major problem for some routes of DMT administration,” said Alejandro Antalich, CEO of Biomind Labs.

He further expanded on the unique potential of BMND01 stating, “The significant reduction in experience duration provides greater practical applicability to potentially deliver the psychedelic treatment in a supervised real-world clinical setting.”

Stay tuned to Psychedelic Chronicle as we keep an eye out for the results in October from Biomind Labs.

The post Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression appeared first on Psychedelic Chronicle.

The news of the recent relationship with Wake Network comes just days after Revitalist announced achieving 300% month-over-month growth in serving veterans with psychedelics in the United States through coverage with the VA (United States Department of Veterans Affairs).

About Wake Network

Wake Network, Inc. is a natural psychedelic-based company that’s vertically integrated and focused on advancing the field of psychedelics in fungi-based and psilocybin therapeutics to address mental health support in medicine and society as a whole.

Wake is currently engaged in pharmaceutical-grade research to provide quality access to all through proprietary genomic and biomarker methods, which are producing fungus-derived psilocybin and medicinal mushroom products.

About Revitalist Lifestyle and Wellness Ltd.

Revitalist Lifestyle and Wellness is one of the largest publicly listed ketamine-focused clinic companies in the United States. Each clinic features psychedelic treatment, vitamin infusions, and other lifestyle improvement treatments provided by doctors and psychologists.

Revitalist has given thousands of ketamine infusions through its network of 9 clinics in six states since it opened its first clinic in 2018. As a specialist behavioral and medical provider, the company’s founder and CEO, Kathryn Walker, works as a lead provider in the psychedelic field as an expert.

The company recently expanded its coverage to better serve mental health and wellness for veterans with financial assistance from the Veterans Health Administration (VHA).

CEO Kathryn Walker stated that with Revitalist’s current contract with the VA the company plans to work with community partners to open more than 100 locations across the nation specifically focusing on Veterans, giving Revitalise access to the VHA budget of over 80 billion dollars.

More than 18 million surviving veterans reside in the United States, with 9 million of them being Veteran Health Administration registrants. Only 4.5 million Veterans utilize their benefits, allowing Revitalist to reach 13.5 million Veterans who are at risk of suicide through preventative services covered by the VA.

Research has indicated that psilocybin and ketamine can improve depression, PTSD, suicidality, anxiety, and other conditions for United States veterans. Approximately 5 million deaths worldwide are attributable to mood and anxiety disorders each year according to a National Institutes of Health meta-analysis.

Revitalist & Wake Network UNIT Retreat

The UNIT Retreat is an eight-day retreat that takes place at the Veteran’s Healing Farm in North Carolina, followed by a five-day psilocybin retreat in Jamaica. The inaugural event takes place October 10-17 to provide follow-up retreats each month.

The retreat has been created to provide quality care promptly with the necessary education tools, research initiatives, and psychedelic medicines to provide ethical access to those in medical need.

Kathryn Walker CEO of Revitalist believes that the ability to offer multiple psychedelic options to the company’s clients will allow them to continue expanding our operations while maintaining a focus on providing ethical access to timely care.

Wake CEO Nick Murray expanded on the partnership stating, “Partnering with the wonderful team at Revitalist delivers on our commitment to furthering care and research to the mental wellness community internationally, through personalized psychedelic treatments.”

The post Revitalist Partners with Wake Network To Offer Psychedelics for Veterans Upon 300% Month over Month Growth appeared first on Psychedelic Chronicle.

The company which focuses on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain confirmed the launch of the trial which is being conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-time in-human studies.

BMB-101 is a next-generation, 5-HT2C selective and biased agonist that exhibits compelling behavioral and preclinical pharmacology and safety data with the potential to be the best-in-class drug. In well-established, predictive animal models, BMB-101 demonstrated a significant reduction in both the number and intensity of epileptic seizures.

The Phase I clinical trial is a randomized, placebo-controlled study of BMB-101 that is currently being conducted in Australia with approximately 76 healthy volunteers. The purpose of the trial is to assess the safety and tolerability of BMB-101 in preparation for Phase II clinical trials.

CEO and Co-founder of Bright Minds Biosciences Ian McDonald was excited about the recent announcement adding commentary regarding the milestone.

“After several years of discovery and early development of next-generation, best-in-class serotonergic investigational drugs, we are delighted to progress into human trials. We are hopeful that our efforts result in more efficacious and safer drugs for patients suffering from Dravet Syndrome, which remains an area of high unmet medical need.”

What is Dravet Syndrome?

Dravet syndrome is an epilepsy disorder that transpires during infancy or early childhood. It can encompass a broad range of effects going from moderate to serious. Children with Dravet syndrome display focal (one-sided) or generalized (all-over) convulsive seizures that commence before they turn 15 months old (frequently before their first birthday).

Gradual onset, partial-brain involvement, and subsequent seizures that move to the other side of the body characterize these initial seizures. These initial fits are sometimes associated with a fever. Other seizure types may appear after 12 months of age and can be quite varied. Status epilepticus – a condition in which there is continual seizure activity requiring immediate medical care – may occur frequently in these youngsters, especially during the first five years of life.

Dravet syndrome affects 1:15,700 people in the United States, or 0.0064% of the population (Wu 2015). Approximately 80-90 percent of those with both an SCN1A mutation and a clinical diagnosis of DS (about 1:20,900 individuals), or 0.17% of all epilepsies.

According to the Food and Drug Administration, there are only three medications that have been approved for the treatment of DS: (1) Fintepla® (fenfluramine), which has a black-box label; (2) Diacomit® (stiripentol); and (3) Epidolex® (cannabidiol).

About Bright Minds

Bright Minds is a psychiatric pharmaceutical company striving to create new treatments for disorders that include, but are not limited to, resistant epilepsy and depression, PTSD, and pain. The company’s portfolio of serotonin agonists specifically targets the neurocircuit abnormalities that contribute to these difficult-to-treat diseases.

Bright Minds advocates for the next generation of safe and effective drugs by using its cutting-edge scientific and drug development skills. The company’s forward-thinking drugs have been created to maintain the potent therapeutic aspects of psychedelic compounds while simultaneously lessening side effects as much as possible, consequently making them better than first-generation serotonergic drugs like psilocybin.

Understanding BMB-101 from Bright Minds

BMB-101, a 5-HT2C selective and biased agonist, has demonstrated impressive activity in several in-vitro and live animal studies. When compared to Locaserin, BMB-101 exhibits much stronger Gq signaling along with minimal beta-arrestin recruitment.

In layman’s terms, serotonin is a monoamine neurotransmitter that has a wide presence in the central nervous system. Drugs regulating serotonin have had significant impacts on mental health disorders.

For many years, the central 5-HT systems have been connected to the management of ingestive behavior and how psychoactive drugs, opioids, alcohol, and nicotine affects someone’s behavior. In only the last decade have we characterized the various 5-HT receptor subtypes.

5-HT2C up receptors agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids and compulsive drug use, according to research.

Chief Medical Officer of Bright Minds Biosciences Dr. Revati Shreeniwas further elaborated on the drug stating, “BMB-101 was designed with the aim of improving the safety profile relative to earlier medications in this class, and we are excited about the potential to deliver an improved therapeutic to address this rare and devastating disease. Based on the strength of BMB-101’s preclinical data and encouraging scientific rationale of 5-HT2C agonism in the treatment of Dravet Syndrome, we are enthusiastic to advance our lead product into clinical trials.”

The post Bright Minds Biosciences Announce Dosing of First Patient in Phase 1 Clinical Trial of BMB-101 for Dravet Syndrome appeared first on Psychedelic Chronicle.

The company which focuses on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, Mindset announced in a press release that through the usage of fragment-based drug discovery (FBDD) method combined with a highly focused medicinal chemistry strategy, Mindset’s scientists designed and developed three new, chemically distinct, small molecule non-tryptamine scaffolds, Families 6, 7, and 8.

The company has filed provisional patent applications on these families, with favorable FTO searches. Approximately forty novel drug-like lead compounds were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies. To date, pre-clinical screening has shown significantly enhanced receptor functional potency and selectivity.

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company striving to create optimized, patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Leveraging the therapeutic potential of psychedelic drugs, Mindset was established to bridge this gap in available treatments.

Mindset is developing several new families of psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 and 4.

Mindset Pharma Future Potential

Mindset believes some of the newly discovered compounds have the potential for greater central nervous system (CNS) penetration, oral activity, and efficacy.

In a recent exclusive interview with Psychedelic Chronicle, CEO James Lanthier discusses the previous 4 families at Mindset Pharma. You can read more here: Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle

Mr. Lanthier also shared a comment today on the breaking news regarding Families 6, 7, and 8 stating,

Mindset’s leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7, and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field.

He further expanded on the discovery highlighting how the discovery will expand the company’s existing pipeline.

The discovery of these new families further expands our rich pipeline and provides a unique serotonergic receptor profile supporting our goal to design new and elegant drug candidates with increased receptor selectivity and potency profiles. Pre-clinical screening of the new families has shown promising results thus far and we are eagerly looking forward to advancing Mindset’s continued innovations into these new, chemically distinct drug families.

Since it was created, Mindset’s ambition has been to be the leading company in medical psychedelic space discovery by expanding the boundaries of known psychedelic drugs to create the most comprehensive portfolio of varied and innovative drug candidates. Most companies in this industry focus on classic psychedelics like tryptamine drugs (psilocybin and DMT), but Mindset hs pushed beyond that into new areas to develop what they believe to be better neuropsychiatric medications.

The post Mindset Pharma Expands IP Portfolio Identifying 3 New Families of Next-Generation Psychedelic Compounds appeared first on Psychedelic Chronicle.